SCHEMBL2629271

SCHEMBL2629271

Cc1cc2ccncc2o1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.51
DYRK1A Q13627 1/20 0.41
NAMPT P43490 9/20 0.36
TDO2 P48775 5/20 0.36
IDO1 P14902 2/20 0.36
CYP2C9 P11712 2/20 0.35
KDM4E B2RXH2 1/20 0.35
NPC1 O15118 1/20 0.35
ALDH1A1 P00352 1/20 0.35
TP53 P04637 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
HPGD P15428 1/20 0.35
CYP2C19 P33261 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
HSD17B10 Q99714 1/20 0.35
CYP2A6 P11509 1/20 0.34
MAOA P21397 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL126266 0.83 MAPT (0.51) MAPTDYRK1ATDO2IDO1CYP2C9
SCHEMBL25748236 0.77 HSD17B3 (0.53) MAPTNAMPTKDM4EALDH1A1CYP1A2
SCHEMBL5955066 0.76 NPC1 (0.46) MAPTNAMPTIDO1CYP2C9NPC1
SCHEMBL19336862 0.75 NAMPT (0.35) MAPTDYRK1ANAMPTCYP2C9KDM4E
SCHEMBL22791609 0.75 NAMPT (0.38) NAMPTTDO2IDO1CYP2C9CYP2A6
SCHEMBL658130 0.75 CDK9 (0.41) DYRK1ANAMPTTDO2IDO1CYP2C9
SCHEMBL18660625 0.75 HASPIN (0.35) MAPTNAMPTTDO2CYP2C9KDM4E
SCHEMBL16901677 0.75 NAMPT (0.40) DYRK1ANAMPTTDO2IDO1CYP2C9
SCHEMBL1763648 0.75 NAMPT (0.35) MAPTDYRK1ANAMPTCYP2C9KDM4E
SCHEMBL24225581 0.75 NR3C1 (0.40) NAMPTIDO1CYP2C9CYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024133560-A1 IMIDAZO[1,2-A]PYRIDINE AND IMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS MLLT1 AND MLLT3 INHIBITORS DARK BLUE THERAPEUTICS LTD (GB) 2024-06-27 WO disclosed
US-20240016953-A1 TARGETED DELIVERY OF NICOTINAMINDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITORS SEAGEN INC (US) 2024-01-18 US disclosed
US-20230346753-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT VALO HEALTH, INC. 2023-11-02 US disclosed
US-20230346753-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT VALO HEALTH, INC. 2023-11-02 US disclosed
EP-4219465-A2 PRMT5 INHIBITORS AND USES THEREOF Epizyme Inc (US) 2023-08-02 EP disclosed
EP-3498701-B1 PRMT5 INHIBITORS AND USES THEREOF EPIZYME INC (US) 2023-02-22 EP disclosed
US-20230047589-A1 INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY ALTOS LABS, INC. 2023-02-16 US disclosed
US-11318133-B2 Modulators of integrated stress response pathway Praxis Biotech LLC (US) 2022-05-03 US disclosed
EP-3642199-B1 BENZOFURANS AS IRAK4 MODULATORS HOFFMANN LA ROCHE (CH) 2022-04-27 EP disclosed
US-11230542-B2 Inhibitors of integrated stress response pathway Praxis Biotech LLC (US) 2022-01-25 US disclosed
US-20070203209-A1 Useful indole compounds IRONWOOD PHARMACEUTICALS, INC. 2007-08-30 US disclosed
US-20070203209-A1 Useful indole compounds IRONWOOD PHARMACEUTICALS, INC. 2007-08-30 US disclosed
US-RE39754-E1 Benzamide derivatives and pharmaceutical compositions containing same SCHERING AG (DE) 2007-07-31 US disclosed
US-RE39754-E1 Benzamide derivatives and pharmaceutical compositions containing same SCHERING AG (DE) 2007-07-31 US disclosed
WO-2007022501-A2 USEFUL INDOLE COMPOUNDS MICROBIA, INC. (US) 2007-02-22 WO disclosed
US-20070010489-A1 Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds GILEAD SCIENCES, INC. 2007-01-11 US disclosed
EP-0847992-B1 Benzamide derivatives, useful as cell differentiation inducers SCHERING AG (DE) 2004-06-23 EP disclosed
US-4577014-A ANTIBIOTICS ELI LILLY AND COMPANY (US) 1986-03-18 US disclosed
US-4501739-A BACTERICIDES, ANTIBIOTICS ELI LILLY AND COMPANY (US) 1985-02-26 US disclosed
EP-0074268-A2 Improvements in or relating to thieno and furopyridinium-substituted cephalosporin derivatives ELI LILLY AND COMPANY (US) 1983-03-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240016953-A1 TARGETED DELIVERY OF NICOTINAMINDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITORS NAMPT, NAPRT, NNMT MAPT 1133/4885DYRK1A 4550/4885NAMPT 1/4885
US-11230542-B2 Inhibitors of integrated stress response pathway ATF4, DDIT3, ATF1 MAPT 4258/4885DYRK1A 2526/4885NAMPT 1994/4885
US-11318133-B2 Modulators of integrated stress response pathway ATF4, ATF1, DDIT3 MAPT 4481/4885DYRK1A 2583/4885NAMPT 2236/4885
US-20230047589-A1 INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY ATF4, DDIT3, ATF1 MAPT 4258/4885DYRK1A 2526/4885NAMPT 1994/4885
US-20070203209-A1 Useful indole compounds TPH2, HRH2, HRH1 MAPT 3076/4885DYRK1A 2204/4885NAMPT 773/4885
US-20070010489-A1 Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds PPA1, PNP, PPME1 MAPT 1076/4885DYRK1A 4116/4885NAMPT 128/4885
US-20230346753-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT NAMPT, NNMT, NQO1 MAPT 519/4885DYRK1A 4847/4885NAMPT 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.